公开(公告)号：US09404090B2

公开(公告)日：2016-08-02

申请号：US14360195

申请日：2012-11-22

申请人： VIROMED CO., LTD.

发明人： Seung Shin Yu ,  Chang-Wan Joo ,  Jin-A Chae ,  Yeon Suk Cha

IPC分类号： C12P21/00 ,  C12N15/86 ,  C12N7/00 ,  C12N5/16 ,  C12N15/12 ,  C12N15/13 ,  C12N5/10

CPC分类号： C12N7/00 ,  C12N15/86 ,  C12N2710/10351 ,  C12P21/00

摘要： The invention relates to a cell line in which an expression construct is introduced into genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus El coding gene sequence of SEQ ID NO: 32 operatively linked to the promoter. The cell line of the invention is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the invention shows superior adenovirus producing ability, as compared with an HEK 293 cell which is one of conventional adenovirus producing cell lines.

摘要翻译： 本发明涉及其中将表达构建体引入基因组DNA的细胞系，该表达构建体包括：（a）可在动物细胞中可操作并且与腺病毒异源的启动子; 和（b）与启动子有效连接的SEQ ID NO：32的修饰的腺病毒E1编码基因序列。 本发明的细胞系不太可能产生复制型腺病毒（RCA）。 与常规细胞系相比，本发明的腺病毒产生细胞系与同源重组产生RCA的可能性低。 因此，这可以在使用腺病毒的基因治疗期间调节所需量的病毒，并防止由腺病毒过量产生引起的组织损伤和毒性作用。 此外，与作为常规腺病毒产生细胞系之一的HEK 293细胞相比，本发明的细胞系显示出优异的腺病毒产生能力。

公开(公告)号：US20140308704A1

公开(公告)日：2014-10-16

申请号：US14360195

申请日：2012-11-22

申请人： VIROMED CO., LTD.

发明人： Seung Shin Yu ,  Chang-Wan Joo ,  Jin-A Chae ,  Yeon Suk Cha

IPC分类号： C12N7/00 ,  C12P21/00

CPC分类号： C12N7/00 ,  C12N15/86 ,  C12N2710/10351 ,  C12P21/00

摘要： The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the present invention shows superior adenovirus producing ability, as compared with an HEK293 cell which is one of conventional adenovirus producing cell lines. Thus, it is possible to produce a time and cost-saving replication incompetent adenovirus. Therefore, the cell line of the present invention effectively produces a replication incompetent adenovirus and provides a safe and effective dose of adenovirus during gene therapy.

摘要翻译： 本发明涉及其中将表达构建体导入基因组DNA的细胞系，该表达构建体包括：（a）可在动物细胞中操作并与腺病毒异源的启动子; 和（b）与启动子可操作地连接的SEQ ID NO：1的修饰的腺病毒E1编码基因序列。 根据本发明，本发明的细胞系是不太可能产生复制型腺病毒（RCA）的新型细胞系。 与常规细胞系相比，本发明的腺病毒产生细胞系与同源重组产生RCA的可能性低。 因此，这可以在使用腺病毒的基因治疗期间调节所需量的病毒，并防止由腺病毒过量产生引起的组织损伤和毒性作用。 此外，与作为常规腺病毒产生细胞系之一的HEK293细胞相比，本发明的细胞系显示出优异的腺病毒产生能力。 因此，可以产生时间和成本节省的复制无能力的腺病毒。 因此，本发明的细胞系有效地产生复制无能的腺病毒，并且在基因治疗期间提供安全有效的腺病毒剂量。